# Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma

> **NCT01744171** · PHASE1 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 10 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IIIB Skin Melanoma
- Stage IIIC Skin Melanoma
- Stage IV Skin Melanoma

## Interventions

- **BIOLOGICAL:** Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01744171
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03-26
- **Primary completion:** 2018-06-11
- **Final completion:** 2018-06-11
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Study was Suspended since 2018; PI decided to terminate.
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01744171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01744171, "Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01744171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*